NEW YORK--(BUSINESS WIRE)--
Kirby McInerney LLP is investigating potential claims against the Board of Directors of Santarus, Inc. (“Santarus” or the “Company”) (SNTS) concerning the proposed acquisition of the Company by Salix Pharmaceuticals, Ltd. (“Salix”). Under the terms of the proposed transaction, Santarus stockholders will receive $32.00 in cash for each share of Santarus owned, valuing the transaction at approximately $2.6 billion.
The investigation concerns whether the Santarus Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $32.00 per share proposed consideration adequately values Santarus’ common stock.
If you are a Santarus stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you.
Kirby McInerney LLP is a New York-based law firm concentrating in securities, stockholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
- Health Care Industry
J. Brandon Walker, Esq., 212-699-1145